

Toward the development of a novel drug using engineered peptides designed for EGFR-mediated drug delivery of an apoptosis inducer in anaplastic thyroid carcinoma

*¹Zehra-Cagla Kahvecioglu, ¹Samuel Vandecasteele, ¹Marine Bougard, ²Sarah Peeters,

¹Alison Daubry, ^{1,3}Sophie Laurent, ³Sven Saussez, ¹Carmen Burtea

¹ Department of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, Faculty of Medicine and Pharmacy, University of Mons

² Cellular and Molecular Microbiology, Faculté des Sciences, Université Libre de Bruxelles

³ Center for Microscopy and Molecular Imaging (CMMI), Faculty of Medicine and Pharmacy, University of Mons

⁴ Department of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, University of Mons

* ZEHRACAGLA.KAHVECIOGLU@umons.ac.be

Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and deadliest thyroid cancer in humans. Mostly affected signaling pathways in ATC are those of MAP kinase and PIP3/AKT/mTOR. The median survival of patients with ATC is of about 4 months after diagnosis. The inefficiency of conventional therapies requires the identification for novel therapeutic approaches that need to be explored.

Aim: The targeted therapy developed in the present work aims to inhibit the PI3K/AKT/mTOR signaling pathway, thereby inducing apoptosis of cancer cells with a therapeutic peptide (TP) developed in our laboratory. The epidermal growth factor receptor (EGFR) is commonly studied in oncology as it is overexpressed in most ATC cells and is actively investigated in the framework of receptor-mediated drug delivery. The EGFR has been associated for years with worse prognosis.

Methods: An EGFR-targeted peptide (vector peptide, VP) was developed by our group and coupled to TP in a peptide complex (PC) to enable the specific drug delivery to ATC cells. VP endocytosis and its effect on EGFR expression and phosphorylation were studied by immunofluorescence (IF) and Western Blot. Caspase 3 activation was observed by IF on ATC cells treated with PC. The molecular mechanism of PV binding to EGFR has been analysed *in silico* by peptide-protein docking studies using the HPEPDOCK web server.

Results: VP has a long half-life and binds to the interface between domains I and III of EGFR, in the large hydrophobic pocket exposing the binding sites to EGF. VP is endocytosed independently of the EGF presence and without activating the EGFR. Within cells, VP is colocalized with EGFR, following its trafficking pathway. Moreover, 10 μ M of PC induces cell apoptosis after 1h of incubation.

Conclusion: To conclude, our studies confirmed that VP is a good EGFR-targeting candidate to deliver TP to cancer cells.

